• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Letter to the editor in response to 'A real-world study of ART in France (REOLA) comparing a biosimilar rFSH against the originator according to rFSH starting dose' by P. Barrière, S. Hamamah, E. Arbo, C. Avril, B. Salle, J.-L. Pouly, et al. (J Gynecol Obstet Hum Reprod. 2023;52(1):102510).

作者信息

Montenegro Susana, Helwig Christoph, Schwarze Juan-Enrique, Castello-Bridoux Claire, Marque Sebastien, Lispi Monica, D'Hooghe Thomas

机构信息

Merck KGaA, Darmstadt, Germany.

Merck KGaA, Darmstadt, Germany.

出版信息

J Gynecol Obstet Hum Reprod. 2023 Oct;52(8):102640. doi: 10.1016/j.jogoh.2023.102640. Epub 2023 Aug 6.

DOI:10.1016/j.jogoh.2023.102640
PMID:37549879
Abstract
摘要

相似文献

1
Letter to the editor in response to 'A real-world study of ART in France (REOLA) comparing a biosimilar rFSH against the originator according to rFSH starting dose' by P. Barrière, S. Hamamah, E. Arbo, C. Avril, B. Salle, J.-L. Pouly, et al. (J Gynecol Obstet Hum Reprod. 2023;52(1):102510).
J Gynecol Obstet Hum Reprod. 2023 Oct;52(8):102640. doi: 10.1016/j.jogoh.2023.102640. Epub 2023 Aug 6.
2
Reply to the letter to the editor in response to 'A real-world study of ART in France (REOLA) comparing a biosimilar rFSH against the originator according to rFSH starting dose' by S. Montenegro, C. Helwig, J.-E. Schwarze, C. Castello-Bridoux, S. Marque, M. Lispi, et al. (J Gynecol Obstet Hum Reprod. 2023;52(8):102640).对S. 黑山、C. 赫尔维格、J.-E. 施瓦泽、C. 卡斯特洛 - 布里杜、S. 马克、M. 利斯皮等人发表于《妇科与产科及人类生殖》（2023年；52(8):102640）的《法国ART的真实世界研究（REOLA）：根据重组促卵泡素起始剂量比较生物类似物重组促卵泡素与原研药》一文致编辑信的回复
J Gynecol Obstet Hum Reprod. 2023 Oct;52(8):102644. doi: 10.1016/j.jogoh.2023.102644. Epub 2023 Aug 11.
3
A real-world study of ART in France (REOLA) comparing a biosimilar rFSH against the originator according to rFSH starting dose.一项在法国开展的关于辅助生殖技术（ART）的真实世界研究（REOLA），根据重组促卵泡激素（rFSH）起始剂量，将一种生物类似药rFSH与原研药进行比较。
J Gynecol Obstet Hum Reprod. 2023 Jan;52(1):102510. doi: 10.1016/j.jogoh.2022.102510. Epub 2022 Nov 17.
4
Determining the cost-effectiveness of follitropin alfa biosimilar compared to follitropin alfa originator in women undergoing fertility treatment in France.确定在法国接受生育治疗的女性中，与重组人促卵泡素α原研药相比，重组人促卵泡素α生物类似药的成本效益。
Eur J Obstet Gynecol Reprod Biol X. 2024 May 3;22:100311. doi: 10.1016/j.eurox.2024.100311. eCollection 2024 Jun.
5
Overlapping biosimilar and originator follitropin alfa preparations: How much closer can they get?重叠的生物类似药和原研促卵泡素 α 制剂：它们能有多接近？
Drug Discov Today. 2022 Aug;27(8):2071-2075. doi: 10.1016/j.drudis.2022.04.022. Epub 2022 Apr 28.
6
A cost-effectiveness modeling evaluation comparing a biosimilar follitropin alfa preparation with its reference product for live birth outcome in Germany, Italy and Spain.一项成本效益模型评估，比较了一种生物类似物重组人促卵泡素α制剂与其参比产品在德国、意大利和西班牙实现活产结局的情况。
J Med Econ. 2018 Nov;21(11):1096-1101. doi: 10.1080/13696998.2018.1511567. Epub 2018 Aug 31.
7
The cumulative live birth rate of recombinant follicle-stimulating hormone alfa verse urinary human follicle-stimulating hormone for ovarian stimulation in assisted reproductive technology cycles.重组促卵泡激素阿尔法与尿源性人促卵泡激素在辅助生殖技术周期中卵巢刺激的累积活产率。
J Ovarian Res. 2022 Jun 21;15(1):74. doi: 10.1186/s13048-022-01009-w.
8
Originator recombinant human follitropin alfa versus recombinant human follitropin alfa biosimilars in Spain: A cost-effectiveness analysis of assisted reproductive technology related to fresh embryo transfers.西班牙原创重组人促卵泡素α与重组人生长激素促卵泡素α生物类似药的比较：与新鲜胚胎移植相关的辅助生殖技术的成本效益分析
Best Pract Res Clin Obstet Gynaecol. 2022 Dec;85(Pt B):203-216. doi: 10.1016/j.bpobgyn.2022.01.011. Epub 2022 Feb 8.
9
Biosimilar recombinant follitropin alfa preparations versus the reference product (Gonal-F®) in couples undergoing assisted reproductive technology treatment: a systematic review and meta-analysis.生物类似重组促卵泡素阿尔法制剂与参照产品（果纳芬®）在接受辅助生殖技术治疗的夫妇中的比较：系统评价和荟萃分析。
Reprod Biol Endocrinol. 2021 Apr 2;19(1):51. doi: 10.1186/s12958-021-00727-y.
10
Different pharmacokinetic and pharmacodynamic properties of recombinant follicle-stimulating hormone (rFSH) derived from a human cell line compared with rFSH from a non-human cell line.源自人细胞系的重组促卵泡激素（rFSH）与源自非人细胞系的rFSH相比，具有不同的药代动力学和药效学特性。
J Clin Pharmacol. 2014 Nov;54(11):1299-307. doi: 10.1002/jcph.328. Epub 2014 May 21.

引用本文的文献

1
A letter to editor - Critical appraisal on "Determining the cost-effectiveness of follitropin alfa biosimilar compared to follitropin alfa originator in women undergoing fertility treatment in France.".致编辑的一封信——对“在法国接受生育治疗的女性中，评估重组人促卵泡激素α生物类似药与重组人促卵泡激素α原研药的成本效益”的批判性评价
Eur J Obstet Gynecol Reprod Biol X. 2024 Aug 2;23:100332. doi: 10.1016/j.eurox.2024.100332. eCollection 2024 Sep.